UK markets open in 1 hour 35 minutes

Astellas Pharma Inc. (ALPMY)

OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
9.39-0.10 (-1.05%)
At close: 03:45PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 17.00B
Enterprise value 20.52B
Trailing P/E 156.54
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.66
Price/book (mrq)1.67
Enterprise value/revenue 2.02
Enterprise value/EBITDA 16.63

Trading information

Stock price history

Beta (5Y monthly) 0.30
52-week change 3-38.30%
S&P500 52-week change 325.87%
52-week high 315.90
52-week low 39.15
50-day moving average 39.74
200-day moving average 311.51

Share statistics

Avg vol (3-month) 3376.9k
Avg vol (10-day) 3397.08k
Shares outstanding 51.79B
Implied shares outstanding 61.81B
Float 81.79B
% held by insiders 10.00%
% held by institutions 10.01%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.46
Forward annual dividend yield 44.91%
Trailing annual dividend rate 370.00
Trailing annual dividend yield 3737.62%
5-year average dividend yield 42.78
Payout ratio 4731.29%
Dividend date 317 Dec 2019
Ex-dividend date 427 Mar 2024
Last split factor 2125:100
Last split date 302 Apr 2014

Financial highlights

Currency in JPY.

Fiscal year

Fiscal year ends 31 Mar 2024
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 1.06%
Operating margin (ttm)-7.98%

Management effectiveness

Return on assets (ttm)1.80%
Return on equity (ttm)1.10%

Income statement

Revenue (ttm)1.6T
Revenue per share (ttm)894.27
Quarterly revenue growth (yoy)17.00%
Gross profit (ttm)N/A
EBITDA 244.7B
Net income avi to common (ttm)17.05B
Diluted EPS (ttm)0.06
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)335.69B
Total cash per share (mrq)187.23
Total debt (mrq)920.02B
Total debt/equity (mrq)57.65%
Current ratio (mrq)0.93
Book value per share (mrq)890.18

Cash flow statement

Operating cash flow (ttm)172.48B
Levered free cash flow (ttm)109.61B